SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA Calendar Updates: ABII, BMRN, JNJ, OSIP, Roche
BMRN
|
|
|
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 254 entries as of 7/13/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
UpDown Virtual Investing: Earn Real Money with Zero Risk
BMRN
|
|
|
<> 
<> The ultimate risk/reward trade for virtual investing – its is free and easy to register at the UpDown and users can earn real money at the site in two ways. The first is by beating the market (S&P 500 Index) on a monthly basis and the second is by referring investors. However, the referral system is designed to encourage legitamte referals only by basing the payment on how much the referred person earns on the site. So, if you refer someone who earns $100, you will receive 10% or $10 as a referral bo...
|
A New Index of Emerging Biotech & Pharma Companies
BMRN
|
|
|
<> 
<>
The accompanying table includes the Top 40 rated companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index, which includes U.S.-listed companies with market caps between $150M-$1.5B and factors in each companies approved products, late-stage clinical pipeline, trailing 52-week stock price performance, and market cap weighting to calculate a stock rating.
The index has performed much better than its peers over the past year for both the Top 40 Rated (-9%) and all 76 companies (-15%) – doing bett< />< /><><>< />< /><>...
|
Bullish on BMRN ...
BMRN
|
|
|
BUSINESS SUMMARY BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company�s product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase i...
|
Biotech Blues: Four Stocks on Sale with Hope
BMRN
|
|
|
<> The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year.
Alnylam Pharma (ALNY): $872M, -31.6%
Biogen Idec (BIIB): $12B, -48.4%
BioMarin Pharma (BMRN): $1.7B, -33%
Momenta Pharma (MNTA): $348M, -23.4%
Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on BMRN |
Visit streetinsider.com
More Resources
|
About BioMarin Pharmaceutical Inc.
- Answers.com
